May 20, 2024
personal mission cancer
M2Gen has a decade’s worth of molecular and clinical data.
personal mission cancer
Researcher Dr. Richard Jove leads the Nova Southeastern University Cell Therapy Institute.

Cancer Care

M2Gen's CEO Wants to Take Personalized Cancer Treatment to the Masses

M2Gen's CEO Wants to Take Personalized Cancer Treatment to the Masses

Art Levy | 2/27/2018

After working more than 30 years in the pharmaceutical and biotech industries, mostly helping to develop anti-cancer drugs, Timothy R. Wright became the CEO of M2Gen last summer. He saw the job, he says, as an opportunity to become a major disruptor.

M2Gen, the Moffitt Cancer Center spinoff, has been building a database of cancer patients’ molecular and clinical data for more than a decade. The data are valuable because they can help pharmaceutical researchers develop drugs targeted to work with each patient’s genetics to best treat their specific cancer — a practice called “personalized medicine.”

Typically, such molecular and clinical patient information isn’t shared among cancer centers, hospitals and pharmaceutical companies, but M2Gen’s database — dubbed the Oncology Research Information Exchange Network (ORIEN) — is challenging that tradition. ORIEN gets data from 17 cancer centers across the country, including Moffitt. Pharmaceutical companies pay to subscribe to the network’s database.

Wright, who came to M2Gen in August from Teva Pharmaceutical Industries, intends to expand ORIEN’s reach. He spoke with Florida Trend about his plans.

  • The Goal: “We generate an enormous amount of very rich data, but we’re just scratching the surface. We have 17 centers now, but there are more than 50 comprehensive cancer centers in the United States. We’re going to continue to expand our relationship with those comprehensive care centers, and we’re going to extend the opportunity to be part of ORIEN to community hospitals. Why is that important? Probably 75% of all cancer patients are treated in community hospitals. By moving ORIEN into the community setting, we can make personalized medicine practical in the community. So someone who doesn’t have access to a Moffitt can still be treated with the same science that they would have had they been treated at Moffitt.

“That’s our responsibility as a company. The other part of my responsibilities is working with the pharmaceutical companies to sign them up so they subscribe to our database. That’s how we generate revenue.”

  • Growth: “We’ll probably double the size of our company over the next 12 months. Many of the types of jobs that we are focused on are data scientists. Probably 70% of our people are IT and data scientists.”
  • The Outlook: “There’s more hope built into cancer over the next 10 years than the last 50. We’re on the verge of something very disruptive in the area of cancer. I also think when you think about other diseases that are huge social issues — like Alzheimer’s — I think this particular approach has application there as well. M2Gen could be, down the road, leading the effort in moving from total cancer care to total health care, using the same underlying organizing principals that we’ve used so far.”

» Next page, Natural Born Killers, and Purifying Stem Cells.

Tags: Healthcare, Life Sciences, Research & Development, Cancer Care, Economic Backbone

Florida Business News

Florida News Releases

Florida Trend Video Pick

FloridaCommerce responds to questions about management of Rebuild Florida program
FloridaCommerce responds to questions about management of Rebuild Florida program

Reporter Jennifer Titus sits down with FloridaCommerce Secretary Alex Kelly and Office of Long-Term Resiliency Director Justin Domer.


Video Picks | Viewpoints@FloridaTrend

Ballot Box

Do you think recreational marijuana should be legal in Florida?

  • Yes, I'm in favor of legalizing marijuana
  • Absolutely not
  • I'm on the fence
  • Other (share thoughts in the comment section below)

See Results

Florida Trend Media Company
490 1st Ave S
St Petersburg, FL 33701

© Copyright 2024 Trend Magazines Inc. All rights reserved.